Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FVD
|
|||
| Former ID |
DCL001019
|
|||
| Drug Name |
TGBA01AD
|
|||
| Synonyms |
ARABINOFURANOSYLURACIL; Spongouridin; 1-pentofuranosylpyrimidine-2,4(1H,3H)-dione; Uracil arabinoside; 3083-77-0; 1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; Uridine-5-d; AK-47314; AC1L1AWE; ACMC-209m8u; 1-.beta.-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione; NCIOpen2_003486; Oprea1_327785; MLS006011814; CHEMBL68846; SCHEMBL2056758; ARONIS003790; AC1Q69D3; KS-00003WPG; CTK8J4890
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Mood disorder [ICD-11: 6A60-6E23; ICD-9: 296] | Phase 2 | [1] | |
| Company |
Fabre-Kramer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H12N2O6
|
|||
| Canonical SMILES |
C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O
|
|||
| InChI |
1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)
|
|||
| InChIKey |
DRTQHJPVMGBUCF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 40436-51-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
82889, 112991, 568053, 619611, 5428231, 8151012, 10528503, 11406095, 11436514, 11450975, 24318726, 24439526, 26960018, 41747568, 47173864, 48334698, 57320796, 57694429, 77021583, 81041252, 85090288, 85090305, 85090306, 85174630, 85209586, 88662377, 92298318, 98571051, 103101967, 104296987, 105040738, 117584552, 125326758, 125347576, 125353805, 125372286, 125482517, 125768177, 126666470, 126677767, 127777606, 134339446, 134340665, 136374571, 136913633, 137176496, 142455558, 162090289, 162092615, 162294370
|
|||
| ChEBI ID |
CHEBI:143353
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Modulator | [2] |
| 5-HT 1D receptor (HTR1D) | Target Info | Modulator | [2] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. | |||
| REF 2 | Company report (Fabrekramer) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.